Reviva reports full year 2023 financial results and recent business highlights

– recover-1 phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia –

RVPH Ratings Summary

RVPH Quant Ranking